<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240122131111&amp;v=2.18.0&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240122131111&amp;v=2.18.0&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Mon, 22 Jan 2024 18:11:13 +0000</lastbuilddate>
<pubDate>Mon, 22 Jan 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38252107/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 22:ehad889. doi: 10.1093/eurheartj/ehad889. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38252107/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38252107</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad889>10.1093/eurheartj/ehad889</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38252107</guid>
<pubDate>Mon, 22 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Neila Sayah</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Michael Miller</dc:creator>
<dc:creator>Eliot A Brinton</dc:creator>
<dc:creator>Terry A Jacobson</dc:creator>
<dc:creator>Steven B Ketchum</dc:creator>
<dc:creator>Lixia Jiao</dc:creator>
<dc:creator>Armando Lira Pineda</dc:creator>
<dc:creator>Ralph T Doyle</dc:creator>
<dc:creator>Jean Claude Tardif</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Ph Gabriel Steg</dc:creator>
<dc:date>2024-01-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial</dc:title>
<dc:identifier>pmid:38252107</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad889</dc:identifier>
</item>
<item>
<title>The American Heart Association Emergency Cardiovascular Care 2030 Impact Goals and Call to Action to Improve Cardiac Arrest Outcomes: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38250800/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>Every 10 years, the American Heart Association (AHA) Emergency Cardiovascular Care Committee establishes goals to improve survival from cardiac arrest. These goals align with broader AHA Impact Goals and support the AHA's advocacy efforts and strategic investments in research, education, clinical care, and quality improvement programs. This scientific statement focuses on 2030 AHA emergency cardiovascular care priorities, with a specific focus on bystander cardiopulmonary resuscitation, early...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 22. doi: 10.1161/CIR.0000000000001196. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Every 10 years, the American Heart Association (AHA) Emergency Cardiovascular Care Committee establishes goals to improve survival from cardiac arrest. These goals align with broader AHA Impact Goals and support the AHA's advocacy efforts and strategic investments in research, education, clinical care, and quality improvement programs. This scientific statement focuses on 2030 AHA emergency cardiovascular care priorities, with a specific focus on bystander cardiopulmonary resuscitation, early defibrillation, and neurologically intact survival. This scientific statement also includes aspirational goals, such as establishing cardiac arrest as a reportable disease and mandating reporting of standardized outcomes from different sources; advancing recognition of and knowledge about cardiac arrest; improving dispatch system response, availability, and access to resuscitation training in multiple settings and at multiple time points; improving availability, access, and affordability of defibrillators; providing a focus on early defibrillation, in-hospital programs, and establishing champions for debriefing and review of cardiac arrest events; and expanding measures to track outcomes beyond survival. The ability to track and report data from these broader aspirational targets will potentially require expansion of existing data sets, development of new data sets, and enhanced integration of technology to collect process and outcome data, as well as partnerships of the AHA with national, state, and local organizations. The COVID-19 (coronavirus disease 2019) pandemic, disparities in COVID-19 outcomes for historically excluded racial and ethnic groups, and the longstanding disparities in cardiac arrest treatment and outcomes for Black and Hispanic or Latino populations also contributed to an explicit focus and target on equity for the AHA Emergency Cardiovascular Care 2030 Impact Goals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38250800/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38250800</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001196>10.1161/CIR.0000000000001196</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38250800</guid>
<pubDate>Mon, 22 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Raina M Merchant</dc:creator>
<dc:creator>Lance B Becker</dc:creator>
<dc:creator>Steven C Brooks</dc:creator>
<dc:creator>Paul S Chan</dc:creator>
<dc:creator>Marina Del Rios</dc:creator>
<dc:creator>Mary E McBride</dc:creator>
<dc:creator>Robert W Neumar</dc:creator>
<dc:creator>Jeanette K Previdi</dc:creator>
<dc:creator>Anezi Uzendu</dc:creator>
<dc:creator>Comilla Sasson</dc:creator>
<dc:creator>American Heart Association</dc:creator>
<dc:date>2024-01-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The American Heart Association Emergency Cardiovascular Care 2030 Impact Goals and Call to Action to Improve Cardiac Arrest Outcomes: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38250800</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001196</dc:identifier>
</item>
<item>
<title>Correction to: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38247449/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 22:ehad857. doi: 10.1093/eurheartj/ehad857. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38247449/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38247449</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad857>10.1093/eurheartj/ehad857</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38247449</guid>
<pubDate>Mon, 22 Jan 2024 06:00:00 -0500</pubDate>
<dc:date>2024-01-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)</dc:title>
<dc:identifier>pmid:38247449</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad857</dc:identifier>
</item>
<item>
<title>Dual phosphorylation of DGK5-mediated PA burst regulates ROS in plant immunity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38244548/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>Phosphatidic acid (PA) and reactive oxygen species (ROS) are crucial cellular messengers mediating diverse signaling processes in metazoans and plants. How PA homeostasis is tightly regulated and intertwined with ROS signaling upon immune elicitation remains elusive. We report here that Arabidopsis diacylglycerol kinase 5 (DGK5) regulates plant pattern-triggered immunity (PTI) and effector-triggered immunity (ETI). The pattern recognition receptor (PRR)-associated kinase BIK1 phosphorylates DGK5...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 11:S0092-8674(23)01404-6. doi: 10.1016/j.cell.2023.12.030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Phosphatidic acid (PA) and reactive oxygen species (ROS) are crucial cellular messengers mediating diverse signaling processes in metazoans and plants. How PA homeostasis is tightly regulated and intertwined with ROS signaling upon immune elicitation remains elusive. We report here that Arabidopsis diacylglycerol kinase 5 (DGK5) regulates plant pattern-triggered immunity (PTI) and effector-triggered immunity (ETI). The pattern recognition receptor (PRR)-associated kinase BIK1 phosphorylates DGK5 at Ser-506, leading to a rapid PA burst and activation of plant immunity, whereas PRR-activated intracellular MPK4 phosphorylates DGK5 at Thr-446, which subsequently suppresses DGK5 activity and PA production, resulting in attenuated plant immunity. PA binds and stabilizes the NADPH oxidase RESPIRATORY BURST OXIDASE HOMOLOG D (RBOHD), regulating ROS production in plant PTI and ETI, and their potentiation. Our data indicate that distinct phosphorylation of DGK5 by PRR-activated BIK1 and MPK4 balances the homeostasis of cellular PA burst that regulates ROS generation in coordinating two branches of plant immunity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38244548/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38244548</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.12.030>10.1016/j.cell.2023.12.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38244548</guid>
<pubDate>Sat, 20 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Liang Kong</dc:creator>
<dc:creator>Xiyu Ma</dc:creator>
<dc:creator>Chao Zhang</dc:creator>
<dc:creator>Sung-Il Kim</dc:creator>
<dc:creator>Bo Li</dc:creator>
<dc:creator>Yingpeng Xie</dc:creator>
<dc:creator>In-Cheol Yeo</dc:creator>
<dc:creator>Hem Thapa</dc:creator>
<dc:creator>Sixue Chen</dc:creator>
<dc:creator>Timothy P Devarenne</dc:creator>
<dc:creator>Teun Munnik</dc:creator>
<dc:creator>Ping He</dc:creator>
<dc:creator>Libo Shan</dc:creator>
<dc:date>2024-01-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Dual phosphorylation of DGK5-mediated PA burst regulates ROS in plant immunity</dc:title>
<dc:identifier>pmid:38244548</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.12.030</dc:identifier>
</item>
<item>
<title>Time resolution in cryo-EM using a PDMS-based microfluidic chip assembly and its application to the study of HflX-mediated ribosome recycling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38244547/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>The rapid kinetics of biological processes and associated short-lived conformational changes pose a significant challenge in attempts to structurally visualize biomolecules during a reaction in real time. Conventionally, on-pathway intermediates have been trapped using chemical modifications or reduced temperature, giving limited insights. Here, we introduce a time-resolved cryo-EM method using a reusable PDMS-based microfluidic chip assembly with high reactant mixing efficiency. Coating of PDMS...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 13:S0092-8674(23)01401-0. doi: 10.1016/j.cell.2023.12.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The rapid kinetics of biological processes and associated short-lived conformational changes pose a significant challenge in attempts to structurally visualize biomolecules during a reaction in real time. Conventionally, on-pathway intermediates have been trapped using chemical modifications or reduced temperature, giving limited insights. Here, we introduce a time-resolved cryo-EM method using a reusable PDMS-based microfluidic chip assembly with high reactant mixing efficiency. Coating of PDMS walls with SiO<sub>2</sub> virtually eliminates non-specific sample adsorption and ensures maintenance of the stoichiometry of the reaction, rendering it highly reproducible. In an operating range from 10 to 1,000 ms, the device allows us to follow in vitro reactions of biological molecules at resolution levels in the range of 3 Å. By employing this method, we show the mechanism of progressive HflX-mediated splitting of the 70S E. coli ribosome in the presence of the GTP via capture of three high-resolution reaction intermediates within 140 ms.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38244547/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38244547</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.12.027>10.1016/j.cell.2023.12.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38244547</guid>
<pubDate>Sat, 20 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Sayan Bhattacharjee</dc:creator>
<dc:creator>Xiangsong Feng</dc:creator>
<dc:creator>Suvrajit Maji</dc:creator>
<dc:creator>Prikshat Dadhwal</dc:creator>
<dc:creator>Zhening Zhang</dc:creator>
<dc:creator>Zuben P Brown</dc:creator>
<dc:creator>Joachim Frank</dc:creator>
<dc:date>2024-01-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Time resolution in cryo-EM using a PDMS-based microfluidic chip assembly and its application to the study of HflX-mediated ribosome recycling</dc:title>
<dc:identifier>pmid:38244547</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.12.027</dc:identifier>
</item>
<item>
<title>Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38243829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>CONCLUSIONS: PTVs influencing ANGPTL3 protein structure as well as common genetic variants influencing ANGPTL3 hepatic expression and/or blood protein levels exhibit a strong effect on circulating plasma triglyceride levels, a weak effect on circulating apoB levels, and no effect on ASCVD. Near-complete inhibition of ANGPTL3 function in patients with very elevated apoB levels may be required to reduce ASCVD risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 19:ehad845. doi: 10.1093/eurheartj/ehad845. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: RNA-based, antibody-based, and genome editing-based therapies are currently under investigation to determine if the inhibition of angiopoietin-like protein-3 (ANGPTL3) could reduce lipoprotein-lipid levels and atherosclerotic cardiovascular disease (ASCVD) risk. Mendelian randomisation (MR) was used to determine whether genetic variations influencing ANGPTL3 liver gene expression, blood levels, and protein structure could causally influence triglyceride and apolipoprotein B (apoB) levels as well as coronary artery disease (CAD), ischaemic stroke (IS), and other cardiometabolic diseases.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: RNA sequencing of 246 explanted liver samples and genome-wide genotyping was performed to identify single-nucleotide polymorphisms (SNPs) associated with liver expression of ANGPTL3. Genome-wide summary statistics of plasma protein levels of ANGPTL3 from the deCODE study (n = 35 359) were used. A total of 647 carriers of ANGPTL3 protein-truncating variants (PTVs) associated with lower plasma triglyceride levels were identified in the UK Biobank. Two-sample MR using SNPs that influence ANGPTL3 liver expression or ANGPTL3 plasma protein levels as exposure and cardiometabolic diseases as outcomes was performed (CAD, IS, heart failure, non-alcoholic fatty liver disease, acute pancreatitis, and type 2 diabetes). The impact of rare PTVs influencing plasma triglyceride levels on apoB levels and CAD was also investigated in the UK Biobank.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In two-sample MR studies, common genetic variants influencing ANGPTL3 hepatic or blood expression levels of ANGPTL3 had a very strong effect on plasma triglyceride levels, a more modest effect on low-density lipoprotein cholesterol, a weaker effect on apoB levels, and no effect on CAD or other cardiometabolic diseases. In the UK Biobank, the carriers of rare ANGPTL3 PTVs providing lifelong reductions in median plasma triglyceride levels [-0.37 (interquartile range 0.41) mmol/L] had slightly lower apoB levels (-0.06 ± 0.32 g/L) and similar CAD event rates compared with non-carriers (10.2% vs. 10.9% in carriers vs. non-carriers, P = .60).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: PTVs influencing ANGPTL3 protein structure as well as common genetic variants influencing ANGPTL3 hepatic expression and/or blood protein levels exhibit a strong effect on circulating plasma triglyceride levels, a weak effect on circulating apoB levels, and no effect on ASCVD. Near-complete inhibition of ANGPTL3 function in patients with very elevated apoB levels may be required to reduce ASCVD risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38243829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38243829</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad845>10.1093/eurheartj/ehad845</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38243829</guid>
<pubDate>Sat, 20 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Émilie Gobeil</dc:creator>
<dc:creator>Jérôme Bourgault</dc:creator>
<dc:creator>Patricia L Mitchell</dc:creator>
<dc:creator>Ursula Houessou</dc:creator>
<dc:creator>Eloi Gagnon</dc:creator>
<dc:creator>Arnaud Girard</dc:creator>
<dc:creator>Audrey Paulin</dc:creator>
<dc:creator>Hasanga D Manikpurage</dc:creator>
<dc:creator>Valérie Côté</dc:creator>
<dc:creator>Christian Couture</dc:creator>
<dc:creator>Simon Marceau</dc:creator>
<dc:creator>Yohan Bossé</dc:creator>
<dc:creator>Sébastien Thériault</dc:creator>
<dc:creator>Patrick Mathieu</dc:creator>
<dc:creator>Marie-Claude Vohl</dc:creator>
<dc:creator>André Tchernof</dc:creator>
<dc:creator>Benoit J Arsenault</dc:creator>
<dc:date>2024-01-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk</dc:title>
<dc:identifier>pmid:38243829</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad845</dc:identifier>
</item>
<item>
<title>Cardiovascular disease risk communication and prevention: a meta-analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38243824/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>CONCLUSIONS: In this systematic review and meta-analysis, communicating CVD risk information, regardless of the method, reduced the overall risk factors and enhanced patients' self-perceived risk. Communication of CVD risk to patients should be considered in routine consultations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 19:ehae002. doi: 10.1093/eurheartj/ehae002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Knowledge of quantifiable cardiovascular disease (CVD) risk may improve health outcomes and trigger behavioural change in patients or clinicians. This review aimed to investigate the impact of CVD risk communication on patient-perceived CVD risk and changes in CVD risk factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: PubMed, Embase, and PsycINFO databases were searched from inception to 6 June 2023, supplemented by citation analysis. Randomized trials that compared any CVD risk communication strategy versus usual care were included. Paired reviewers independently screened the identified records and extracted the data; disagreements were resolved by a third author. The primary outcome was the accuracy of risk perception. Secondary outcomes were clinician-reported changes in CVD risk, psychological responses, intention to modify lifestyle, and self-reported changes in risk factors and clinician prescribing of preventive medicines.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Sixty-two trials were included. Accuracy of risk perception was higher among intervention participants (odds ratio = 2.31, 95% confidence interval = 1.63 to 3.27). A statistically significant improvement in overall CVD risk scores was found at 6-12 months (mean difference = -0.27, 95% confidence interval = -0.45 to -0.09). For primary prevention, risk communication significantly increased self-reported dietary modification (odds ratio = 1.50, 95% confidence interval = 1.21 to 1.86) with no increase in intention or actual changes in smoking cessation or physical activity. A significant impact on patients' intention to start preventive medication was found for primary and secondary prevention, with changes at follow-up for the primary prevention group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this systematic review and meta-analysis, communicating CVD risk information, regardless of the method, reduced the overall risk factors and enhanced patients' self-perceived risk. Communication of CVD risk to patients should be considered in routine consultations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38243824/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38243824</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae002>10.1093/eurheartj/ehae002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38243824</guid>
<pubDate>Sat, 20 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Mina Bakhit</dc:creator>
<dc:creator>Samantha Fien</dc:creator>
<dc:creator>Eman Abukmail</dc:creator>
<dc:creator>Mark Jones</dc:creator>
<dc:creator>Justin Clark</dc:creator>
<dc:creator>Anna Mae Scott</dc:creator>
<dc:creator>Paul Glasziou</dc:creator>
<dc:creator>Magnolia Cardona</dc:creator>
<dc:date>2024-01-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiovascular disease risk communication and prevention: a meta-analysis</dc:title>
<dc:identifier>pmid:38243824</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae002</dc:identifier>
</item>
<item>
<title>Mitral transcatheter edge to edge repair versus isolated mitral surgery for severe mitral regurgitation: A French nationwide study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38243821/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>CONCLUSIONS: Our results suggest that TEER for severe mitral regurgitation was associated with lower cardiovascular mortality than mitral surgery at long-term follow-up. Pacemaker implantation and stroke were less frequently observed after TEER.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 19:ehae046. doi: 10.1093/eurheartj/ehae046. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Mitral valve surgery and more recently mitral transcatheter edge-to-edge repair (TEER) are the two treatments of severe mitral regurgitation in eligible patients. Clinical comparison of both therapies remains limited by the number of patients analysed. The objective of this study was to analyse the outcomes of mitral TEER versus isolated mitral valve surgery at a nationwide level in France.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Based on the French administrative hospital-discharge database, the study collected information for all consecutive patients treated for mitral regurgitation with isolated TEER or isolated mitral valve surgery between 2012 and 2022. Propensity score matching was used for the analysis of outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 57,030 patients were found in the database. After matching on baseline characteristics, 2,160 patients were analysed in each arm. At 3-year follow-up, TEER was associated with significantly lower incidence of cardiovascular death (HR 0.685, 95% CI 0.563-0.832; p &lt; 0.001), pacemaker implantation and stroke. Non-cardiovascular death (HR 1.562, 95% CI 1.238-1.971; p = 0.0001), recurrent pulmonary edema and cardiac arrest were more frequent after TEER. No significant differences between the two groups were observed regarding all-cause death (HR 0.967, 95% CI 0.835-1.118; p = 0.65), endocarditis, major bleeding and atrial fibrillation and myocardial infarction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results suggest that TEER for severe mitral regurgitation was associated with lower cardiovascular mortality than mitral surgery at long-term follow-up. Pacemaker implantation and stroke were less frequently observed after TEER.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38243821/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38243821</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae046>10.1093/eurheartj/ehae046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38243821</guid>
<pubDate>Sat, 20 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Pierre Deharo</dc:creator>
<dc:creator>Jean Francois Obadia</dc:creator>
<dc:creator>Patrice Guerin</dc:creator>
<dc:creator>Thomas Cuisset</dc:creator>
<dc:creator>Jean Francois Avierinos</dc:creator>
<dc:creator>Gilbert Habib</dc:creator>
<dc:creator>Olivier Torras</dc:creator>
<dc:creator>Arnaud Bisson</dc:creator>
<dc:creator>Pascal Vigny</dc:creator>
<dc:creator>Christophe Saint Etienne</dc:creator>
<dc:creator>Carl Semaan</dc:creator>
<dc:creator>Mickael Guglieri</dc:creator>
<dc:creator>Nicolas Dumonteil</dc:creator>
<dc:creator>Frederic Collart</dc:creator>
<dc:creator>Martine Gilard</dc:creator>
<dc:creator>Thomas Modine</dc:creator>
<dc:creator>Erwan Donal</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Laurent Fauchier</dc:creator>
<dc:date>2024-01-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mitral transcatheter edge to edge repair versus isolated mitral surgery for severe mitral regurgitation: A French nationwide study</dc:title>
<dc:identifier>pmid:38243821</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae046</dc:identifier>
</item>
<item>
<title>Drugging the foam cell: identifying P2Y6 antagonists that limit atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38243806/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 19:ehad846. doi: 10.1093/eurheartj/ehad846. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38243806/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38243806</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad846>10.1093/eurheartj/ehad846</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38243806</guid>
<pubDate>Sat, 20 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Katey J Rayner</dc:creator>
<dc:date>2024-01-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Drugging the foam cell: identifying P2Y6 antagonists that limit atherosclerosis</dc:title>
<dc:identifier>pmid:38243806</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad846</dc:identifier>
</item>
<item>
<title>Cardiology's new crystal ball: machine learning for outcome prediction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38243801/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 19:ehad847. doi: 10.1093/eurheartj/ehad847. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38243801/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38243801</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad847>10.1093/eurheartj/ehad847</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38243801</guid>
<pubDate>Sat, 20 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Patrick W Serruys</dc:creator>
<dc:creator>Shigetaka Kageyama</dc:creator>
<dc:creator>Yoshinobu Onuma</dc:creator>
<dc:date>2024-01-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiology's new crystal ball: machine learning for outcome prediction</dc:title>
<dc:identifier>pmid:38243801</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad847</dc:identifier>
</item>
<item>
<title>Artificial intelligence-derived risk score for mortality in secondary mitral regurgitation treated by transcatheter edge-to-edge repair: the EuroSMR risk score</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38243773/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>CONCLUSIONS: The EuroSMR risk score may allow for improved prognostication in heart failure patients with severe SMR, who are considered for a M-TEER procedure. The score is expected to facilitate the shared decision-making process with heart team members and patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 19:ehad871. doi: 10.1093/eurheartj/ehad871. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Risk stratification for mitral valve transcatheter edge-to-edge repair (M-TEER) is paramount in the decision-making process to appropriately select patients with severe secondary mitral regurgitation (SMR). This study sought to develop and validate an artificial intelligence-derived risk score (EuroSMR score) to predict 1-year outcomes (survival or survival + clinical improvement) in patients with SMR undergoing M-TEER.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: An artificial intelligence-derived risk score was developed from the EuroSMR cohort (4172 and 428 patients treated with M-TEER in the derivation and validation cohorts, respectively). The EuroSMR score was validated and compared with established risk models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The EuroSMR risk score, which is based on 18 clinical, echocardiographic, laboratory, and medication parameters, allowed for an improved discrimination of surviving and non-surviving patients (hazard ratio 4.3, 95% confidence interval 3.7-5.0; P &lt; .001), and outperformed established risk scores in the validation cohort. Prediction for 1-year mortality (area under the curve: 0.789, 95% confidence interval 0.737-0.842) ranged from &lt;5% to >;70%, including the identification of an extreme-risk population (2.6% of the entire cohort), which had a very high probability for not surviving beyond 1 year (hazard ratio 6.5, 95% confidence interval 3.0-14; P &lt; .001). The top 5% of patients with the highest EuroSMR risk scores showed event rates of 72.7% for mortality and 83.2% for mortality or lack of clinical improvement at 1-year follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The EuroSMR risk score may allow for improved prognostication in heart failure patients with severe SMR, who are considered for a M-TEER procedure. The score is expected to facilitate the shared decision-making process with heart team members and patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38243773/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38243773</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad871>10.1093/eurheartj/ehad871</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38243773</guid>
<pubDate>Sat, 20 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:creator>Mark Lachmann</dc:creator>
<dc:creator>Lukas Stolz</dc:creator>
<dc:creator>Francesco Bedogni</dc:creator>
<dc:creator>Antonio P Rubbio</dc:creator>
<dc:creator>Rodrigo Estévez-Loureiro</dc:creator>
<dc:creator>Sergio Raposeiras-Roubin</dc:creator>
<dc:creator>Peter Boekstegers</dc:creator>
<dc:creator>Nicole Karam</dc:creator>
<dc:creator>Volker Rudolph</dc:creator>
<dc:creator>EuroSMR Investigators</dc:creator>
<dc:date>2024-01-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence-derived risk score for mortality in secondary mitral regurgitation treated by transcatheter edge-to-edge repair: the EuroSMR risk score</dc:title>
<dc:identifier>pmid:38243773</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad871</dc:identifier>
</item>
<item>
<title>Rapid onset of takotsubo cardiomyopathy induced by left bundle branch area pacing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38242859/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 18:ehad893. doi: 10.1093/eurheartj/ehad893. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38242859/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38242859</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad893>10.1093/eurheartj/ehad893</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38242859</guid>
<pubDate>Fri, 19 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Yi-Pan Li</dc:creator>
<dc:creator>Ju-Yi Chen</dc:creator>
<dc:date>2024-01-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rapid onset of takotsubo cardiomyopathy induced by left bundle branch area pacing</dc:title>
<dc:identifier>pmid:38242859</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad893</dc:identifier>
</item>
<item>
<title>Functionally bicuspid aortic valve leads to myocardial ischaemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38242858/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 18:ehad891. doi: 10.1093/eurheartj/ehad891. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38242858/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38242858</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad891>10.1093/eurheartj/ehad891</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38242858</guid>
<pubDate>Fri, 19 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Zihao Li</dc:creator>
<dc:creator>Hongwei Zhang</dc:creator>
<dc:creator>Simin Lin</dc:creator>
<dc:date>2024-01-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Functionally bicuspid aortic valve leads to myocardial ischaemia</dc:title>
<dc:identifier>pmid:38242858</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad891</dc:identifier>
</item>
<item>
<title>Edoxaban-induced oesophagitis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38242856/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 18:ehad892. doi: 10.1093/eurheartj/ehad892. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38242856/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38242856</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad892>10.1093/eurheartj/ehad892</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38242856</guid>
<pubDate>Fri, 19 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Yusaku Kajihara</dc:creator>
<dc:date>2024-01-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Edoxaban-induced oesophagitis</dc:title>
<dc:identifier>pmid:38242856</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad892</dc:identifier>
</item>
<item>
<title>Complement in breast milk modifies offspring gut microbiota to promote infant health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38242132/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>Breastfeeding offers demonstrable benefits to newborns and infants by providing nourishment and immune protection and by shaping the gut commensal microbiota. Although it has been appreciated for decades that breast milk contains complement components, the physiological relevance of complement in breast milk remains undefined. Here, we demonstrate that weanling mice fostered by complement-deficient dams rapidly succumb when exposed to murine pathogen Citrobacter rodentium (CR), whereas pups...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 10:S0092-8674(23)01384-3. doi: 10.1016/j.cell.2023.12.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Breastfeeding offers demonstrable benefits to newborns and infants by providing nourishment and immune protection and by shaping the gut commensal microbiota. Although it has been appreciated for decades that breast milk contains complement components, the physiological relevance of complement in breast milk remains undefined. Here, we demonstrate that weanling mice fostered by complement-deficient dams rapidly succumb when exposed to murine pathogen Citrobacter rodentium (CR), whereas pups fostered on complement-containing milk complement components in breast milk were shown to directly lyse specific members of gram-positive gut commensal microbiota via a C1-dependent, antibody-independent mechanism, resulting in the deposition of the membrane attack complex and subsequent bacterial lysis. By selectively eliminating members of the commensal gut community, complement components from breast milk shape neonate and infant gut microbial composition to be protective against environmental pathogens such as CR.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38242132/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38242132</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.12.019>10.1016/j.cell.2023.12.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38242132</guid>
<pubDate>Fri, 19 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Dongqing Xu</dc:creator>
<dc:creator>Siyu Zhou</dc:creator>
<dc:creator>Yue Liu</dc:creator>
<dc:creator>Alan L Scott</dc:creator>
<dc:creator>Jian Yang</dc:creator>
<dc:creator>Fengyi Wan</dc:creator>
<dc:date>2024-01-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Complement in breast milk modifies offspring gut microbiota to promote infant health</dc:title>
<dc:identifier>pmid:38242132</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.12.019</dc:identifier>
</item>
<item>
<title>Autism-related dietary preferences mediate autism-gut microbiome associations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38242089/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 18;187(2):495-510. doi: 10.1016/j.cell.2023.12.001.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38242089/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38242089</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.12.001>10.1016/j.cell.2023.12.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38242089</guid>
<pubDate>Fri, 19 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Chloe X Yap</dc:creator>
<dc:creator>Anjali K Henders</dc:creator>
<dc:creator>Gail A Alvares</dc:creator>
<dc:creator>David L A Wood</dc:creator>
<dc:creator>Lutz Krause</dc:creator>
<dc:creator>Gene W Tyson</dc:creator>
<dc:creator>Restuadi Restuadi</dc:creator>
<dc:creator>Leanne Wallace</dc:creator>
<dc:creator>Tiana McLaren</dc:creator>
<dc:creator>Narelle K Hansell</dc:creator>
<dc:creator>Dominique Cleary</dc:creator>
<dc:creator>Rachel Grove</dc:creator>
<dc:creator>Claire Hafekost</dc:creator>
<dc:creator>Alexis Harun</dc:creator>
<dc:creator>Helen Holdsworth</dc:creator>
<dc:creator>Rachel Jellett</dc:creator>
<dc:creator>Feroza Khan</dc:creator>
<dc:creator>Lauren P Lawson</dc:creator>
<dc:creator>Jodie Leslie</dc:creator>
<dc:creator>Mira Levis Frenk</dc:creator>
<dc:creator>Anne Masi</dc:creator>
<dc:creator>Nisha E Mathew</dc:creator>
<dc:creator>Melanie Muniandy</dc:creator>
<dc:creator>Michaela Nothard</dc:creator>
<dc:creator>Jessica L Miller</dc:creator>
<dc:creator>Lorelle Nunn</dc:creator>
<dc:creator>Gerald Holtmann</dc:creator>
<dc:creator>Lachlan T Strike</dc:creator>
<dc:creator>Greig I de Zubicaray</dc:creator>
<dc:creator>Paul M Thompson</dc:creator>
<dc:creator>Katie L McMahon</dc:creator>
<dc:creator>Margaret J Wright</dc:creator>
<dc:creator>Peter M Visscher</dc:creator>
<dc:creator>Paul A Dawson</dc:creator>
<dc:creator>Cheryl Dissanayake</dc:creator>
<dc:creator>Valsamma Eapen</dc:creator>
<dc:creator>Helen S Heussler</dc:creator>
<dc:creator>Allan F McRae</dc:creator>
<dc:creator>Andrew J O Whitehouse</dc:creator>
<dc:creator>Naomi R Wray</dc:creator>
<dc:creator>Jacob Gratten</dc:creator>
<dc:date>2024-01-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Autism-related dietary preferences mediate autism-gut microbiome associations</dc:title>
<dc:identifier>pmid:38242089</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.12.001</dc:identifier>
</item>
<item>
<title>A multi-cohort genome-wide association study in African ancestry individuals reveals risk loci for primary open-angle glaucoma</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38242088/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>Primary open-angle glaucoma (POAG), the leading cause of irreversible blindness worldwide, disproportionately affects individuals of African ancestry. We conducted a genome-wide association study (GWAS) for POAG in 11,275 individuals of African ancestry (6,003 cases; 5,272 controls). We detected 46 risk loci associated with POAG at genome-wide significance. Replication and post-GWAS analyses, including functionally informed fine-mapping, multiple trait co-localization, and in silico validation,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 18;187(2):464-480.e10. doi: 10.1016/j.cell.2023.12.006.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Primary open-angle glaucoma (POAG), the leading cause of irreversible blindness worldwide, disproportionately affects individuals of African ancestry. We conducted a genome-wide association study (GWAS) for POAG in 11,275 individuals of African ancestry (6,003 cases; 5,272 controls). We detected 46 risk loci associated with POAG at genome-wide significance. Replication and post-GWAS analyses, including functionally informed fine-mapping, multiple trait co-localization, and in silico validation, implicated two previously undescribed variants (rs1666698 mapping to DBF4P2; rs34957764 mapping to ROCK1P1) and one previously associated variant (rs11824032 mapping to ARHGEF12) as likely causal. For individuals of African ancestry, a polygenic risk score (PRS) for POAG from our mega-analysis (African ancestry individuals) outperformed a PRS from summary statistics of a much larger GWAS derived from European ancestry individuals. This study quantifies the genetic architecture similarities and differences between African and non-African ancestry populations for this blinding disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38242088/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38242088</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.12.006>10.1016/j.cell.2023.12.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38242088</guid>
<pubDate>Fri, 19 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Shefali S Verma</dc:creator>
<dc:creator>Harini V Gudiseva</dc:creator>
<dc:creator>Venkata R M Chavali</dc:creator>
<dc:creator>Rebecca J Salowe</dc:creator>
<dc:creator>Yuki Bradford</dc:creator>
<dc:creator>Lindsay Guare</dc:creator>
<dc:creator>Anastasia Lucas</dc:creator>
<dc:creator>David W Collins</dc:creator>
<dc:creator>Vrathasha Vrathasha</dc:creator>
<dc:creator>Rohini M Nair</dc:creator>
<dc:creator>Sonika Rathi</dc:creator>
<dc:creator>Bingxin Zhao</dc:creator>
<dc:creator>Jie He</dc:creator>
<dc:creator>Roy Lee</dc:creator>
<dc:creator>Selam Zenebe-Gete</dc:creator>
<dc:creator>Anita S Bowman</dc:creator>
<dc:creator>Caitlin P McHugh</dc:creator>
<dc:creator>Michael C Zody</dc:creator>
<dc:creator>Maxwell Pistilli</dc:creator>
<dc:creator>Naira Khachatryan</dc:creator>
<dc:creator>Ebenezer Daniel</dc:creator>
<dc:creator>Windell Murphy</dc:creator>
<dc:creator>Jeffrey Henderer</dc:creator>
<dc:creator>Regeneron Genetics Center</dc:creator>
<dc:creator>Tyler G Kinzy</dc:creator>
<dc:creator>Sudha K Iyengar</dc:creator>
<dc:creator>Neal S Peachey</dc:creator>
<dc:creator>VA Million Veteran Program</dc:creator>
<dc:creator>Kent D Taylor</dc:creator>
<dc:creator>Xiuqing Guo</dc:creator>
<dc:creator>Yii-Der Ida Chen</dc:creator>
<dc:creator>Linda Zangwill</dc:creator>
<dc:creator>Christopher Girkin</dc:creator>
<dc:creator>Radha Ayyagari</dc:creator>
<dc:creator>Jeffrey Liebmann</dc:creator>
<dc:creator>Chimd M Chuka-Okosa</dc:creator>
<dc:creator>Susan E Williams</dc:creator>
<dc:creator>Stephen Akafo</dc:creator>
<dc:creator>Donald L Budenz</dc:creator>
<dc:creator>Olusola O Olawoye</dc:creator>
<dc:creator>Michele Ramsay</dc:creator>
<dc:creator>Adeyinka Ashaye</dc:creator>
<dc:creator>Onoja M Akpa</dc:creator>
<dc:creator>Tin Aung</dc:creator>
<dc:creator>Janey L Wiggs</dc:creator>
<dc:creator>Ahmara G Ross</dc:creator>
<dc:creator>Qi N Cui</dc:creator>
<dc:creator>Victoria Addis</dc:creator>
<dc:creator>Amanda Lehman</dc:creator>
<dc:creator>Eydie Miller-Ellis</dc:creator>
<dc:creator>Prithvi S Sankar</dc:creator>
<dc:creator>Scott M Williams</dc:creator>
<dc:creator>Gui-Shuang Ying</dc:creator>
<dc:creator>Jessica Cooke Bailey</dc:creator>
<dc:creator>Jerome I Rotter</dc:creator>
<dc:creator>Robert Weinreb</dc:creator>
<dc:creator>Chiea Chuen Khor</dc:creator>
<dc:creator>Michael A Hauser</dc:creator>
<dc:creator>Marylyn D Ritchie</dc:creator>
<dc:creator>Joan M O'Brien</dc:creator>
<dc:date>2024-01-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A multi-cohort genome-wide association study in African ancestry individuals reveals risk loci for primary open-angle glaucoma</dc:title>
<dc:identifier>pmid:38242088</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.12.006</dc:identifier>
</item>
<item>
<title>Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38242087/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>Treatment failure for the lethal brain tumor glioblastoma (GBM) is attributed to intratumoral heterogeneity and tumor evolution. We utilized 3D neuronavigation during surgical resection to acquire samples representing the whole tumor mapped by 3D spatial coordinates. Integrative tissue and single-cell analysis revealed sources of genomic, epigenomic, and microenvironmental intratumoral heterogeneity and their spatial patterning. By distinguishing tumor-wide molecular features from those with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 18;187(2):446-463.e16. doi: 10.1016/j.cell.2023.12.013.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Treatment failure for the lethal brain tumor glioblastoma (GBM) is attributed to intratumoral heterogeneity and tumor evolution. We utilized 3D neuronavigation during surgical resection to acquire samples representing the whole tumor mapped by 3D spatial coordinates. Integrative tissue and single-cell analysis revealed sources of genomic, epigenomic, and microenvironmental intratumoral heterogeneity and their spatial patterning. By distinguishing tumor-wide molecular features from those with regional specificity, we inferred GBM evolutionary trajectories from neurodevelopmental lineage origins and initiating events such as chromothripsis to emergence of genetic subclones and spatially restricted activation of differential tumor and microenvironmental programs in the core, periphery, and contrast-enhancing regions. Our work depicts GBM evolution and heterogeneity from a 3D whole-tumor perspective, highlights potential therapeutic targets that might circumvent heterogeneity-related failures, and establishes an interactive platform enabling 360° visualization and analysis of 3D spatial patterns for user-selected genes, programs, and other features across whole GBM tumors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38242087/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38242087</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.12.013>10.1016/j.cell.2023.12.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38242087</guid>
<pubDate>Fri, 19 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Radhika Mathur</dc:creator>
<dc:creator>Qixuan Wang</dc:creator>
<dc:creator>Patrick G Schupp</dc:creator>
<dc:creator>Ana Nikolic</dc:creator>
<dc:creator>Stephanie Hilz</dc:creator>
<dc:creator>Chibo Hong</dc:creator>
<dc:creator>Nadia R Grishanina</dc:creator>
<dc:creator>Darwin Kwok</dc:creator>
<dc:creator>Nicholas O Stevers</dc:creator>
<dc:creator>Qiushi Jin</dc:creator>
<dc:creator>Mark W Youngblood</dc:creator>
<dc:creator>Lena Ann Stasiak</dc:creator>
<dc:creator>Ye Hou</dc:creator>
<dc:creator>Juan Wang</dc:creator>
<dc:creator>Takafumi N Yamaguchi</dc:creator>
<dc:creator>Marisa Lafontaine</dc:creator>
<dc:creator>Anny Shai</dc:creator>
<dc:creator>Ivan V Smirnov</dc:creator>
<dc:creator>David A Solomon</dc:creator>
<dc:creator>Susan M Chang</dc:creator>
<dc:creator>Shawn L Hervey-Jumper</dc:creator>
<dc:creator>Mitchel S Berger</dc:creator>
<dc:creator>Janine M Lupo</dc:creator>
<dc:creator>Hideho Okada</dc:creator>
<dc:creator>Joanna J Phillips</dc:creator>
<dc:creator>Paul C Boutros</dc:creator>
<dc:creator>Marco Gallo</dc:creator>
<dc:creator>Michael C Oldham</dc:creator>
<dc:creator>Feng Yue</dc:creator>
<dc:creator>Joseph F Costello</dc:creator>
<dc:date>2024-01-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective</dc:title>
<dc:identifier>pmid:38242087</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.12.013</dc:identifier>
</item>
<item>
<title>Coordinating brain-distributed network activities in memory resistant to extinction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38242086/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>Certain memories resist extinction to continue invigorating maladaptive actions. The robustness of these memories could depend on their widely distributed implementation across populations of neurons in multiple brain regions. However, how dispersed neuronal activities are collectively organized to underpin a persistent memory-guided behavior remains unknown. To investigate this, we simultaneously monitored the prefrontal cortex, nucleus accumbens, amygdala, hippocampus, and ventral tegmental...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 18;187(2):409-427.e19. doi: 10.1016/j.cell.2023.12.018.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Certain memories resist extinction to continue invigorating maladaptive actions. The robustness of these memories could depend on their widely distributed implementation across populations of neurons in multiple brain regions. However, how dispersed neuronal activities are collectively organized to underpin a persistent memory-guided behavior remains unknown. To investigate this, we simultaneously monitored the prefrontal cortex, nucleus accumbens, amygdala, hippocampus, and ventral tegmental area (VTA) of the mouse brain from initial recall to post-extinction renewal of a memory involving cocaine experience. We uncover a higher-order pattern of short-lived beta-frequency (15-25 Hz) activities that are transiently coordinated across these networks during memory retrieval. The output of a divergent pathway from upstream VTA glutamatergic neurons, paced by a slower (4-Hz) oscillation, actuates this multi-network beta-band coactivation; its closed-loop phase-informed suppression prevents renewal of cocaine-biased behavior. Binding brain-distributed neural activities in this temporally structured manner may constitute an organizational principle of robust memory expression.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38242086/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38242086</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.12.018>10.1016/j.cell.2023.12.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38242086</guid>
<pubDate>Fri, 19 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Charlie J Clarke-Williams</dc:creator>
<dc:creator>Vítor Lopes-Dos-Santos</dc:creator>
<dc:creator>Laura Lefèvre</dc:creator>
<dc:creator>Demi Brizee</dc:creator>
<dc:creator>Adrien A Causse</dc:creator>
<dc:creator>Roman Rothaermel</dc:creator>
<dc:creator>Katja Hartwich</dc:creator>
<dc:creator>Pavel V Perestenko</dc:creator>
<dc:creator>Robert Toth</dc:creator>
<dc:creator>Colin G McNamara</dc:creator>
<dc:creator>Andrew Sharott</dc:creator>
<dc:creator>David Dupret</dc:creator>
<dc:date>2024-01-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Coordinating brain-distributed network activities in memory resistant to extinction</dc:title>
<dc:identifier>pmid:38242086</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.12.018</dc:identifier>
</item>
<item>
<title>Bispecific dendritic-T cell engager potentiates anti-tumor immunity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38242085/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>Immune checkpoint inhibition treatment using aPD-1 monoclonal antibodies is a promising cancer immunotherapy approach. However, its effect on tumor immunity is narrow, as most patients do not respond to the treatment or suffer from recurrence. We show that the crosstalk between conventional type I dendritic cells (cDC1) and T cells is essential for an effective aPD-1-mediated anti-tumor response. Accordingly, we developed a bispecific DC-T cell engager (BiCE), a reagent that facilitates physical...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 18;187(2):375-389.e18. doi: 10.1016/j.cell.2023.12.011.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Immune checkpoint inhibition treatment using aPD-1 monoclonal antibodies is a promising cancer immunotherapy approach. However, its effect on tumor immunity is narrow, as most patients do not respond to the treatment or suffer from recurrence. We show that the crosstalk between conventional type I dendritic cells (cDC1) and T cells is essential for an effective aPD-1-mediated anti-tumor response. Accordingly, we developed a bispecific DC-T cell engager (BiCE), a reagent that facilitates physical interactions between PD-1<sup>+</sup> T cells and cDC1. BiCE treatment promotes the formation of active dendritic/T cell crosstalk in the tumor and tumor-draining lymph nodes. In vivo, single-cell and physical interacting cell analysis demonstrates the distinct and superior immune reprogramming of the tumors and tumor-draining lymph nodes treated with BiCE as compared to conventional aPD-1 treatment. By bridging immune cells, BiCE potentiates cell circuits and communication pathways needed for effective anti-tumor immunity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38242085/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38242085</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.12.011>10.1016/j.cell.2023.12.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38242085</guid>
<pubDate>Fri, 19 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Yuval Shapir Itai</dc:creator>
<dc:creator>Oren Barboy</dc:creator>
<dc:creator>Ran Salomon</dc:creator>
<dc:creator>Akhiad Bercovich</dc:creator>
<dc:creator>Ken Xie</dc:creator>
<dc:creator>Eitan Winter</dc:creator>
<dc:creator>Tamar Shami</dc:creator>
<dc:creator>Ziv Porat</dc:creator>
<dc:creator>Neta Erez</dc:creator>
<dc:creator>Amos Tanay</dc:creator>
<dc:creator>Ido Amit</dc:creator>
<dc:creator>Rony Dahan</dc:creator>
<dc:date>2024-01-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Bispecific dendritic-T cell engager potentiates anti-tumor immunity</dc:title>
<dc:identifier>pmid:38242085</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.12.011</dc:identifier>
</item>
<item>
<title>Making glaucoma genetic studies more diverse</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38242084/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240122131111&amp;v=2.18.0
      <description>Although the blinding eye disease glaucoma is more common in people of African ancestry, previous genetic studies predominantly involved European subjects. In this issue of Cell, O'Brien et al. report a genome-wide association study for glaucoma in individuals of African ancestry, showing overlap with European studies and refining an African polygenic risk score.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 18;187(2):273-275. doi: 10.1016/j.cell.2023.12.023.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Although the blinding eye disease glaucoma is more common in people of African ancestry, previous genetic studies predominantly involved European subjects. In this issue of Cell, O'Brien et al. report a genome-wide association study for glaucoma in individuals of African ancestry, showing overlap with European studies and refining an African polygenic risk score.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38242084/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240122131111&v=2.18.0">38242084</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.12.023>10.1016/j.cell.2023.12.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38242084</guid>
<pubDate>Fri, 19 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>David A Mackey</dc:creator>
<dc:creator>Sandra E Staffieri</dc:creator>
<dc:date>2024-01-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Making glaucoma genetic studies more diverse</dc:title>
<dc:identifier>pmid:38242084</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.12.023</dc:identifier>
</item>





























</channel>
</rss>